Immunology News and Research

Latest Immunology News and Research

Latest studies in the field of allergy and clinical immunology to be presented at EAACI Congress 2012

The latest studies in the field of allergy and clinical immunology will be presented at the EAACI Congress 2012.

5 Jun 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer.

5 Jun 2012

$Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML$

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations.

5 Jun 2012

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.

4 Jun 2012

ZYTIGA Phase 3 study for metastatic prostate cancer presented at 48th ASCO

New data presented this weekend at the 48th annual meeting of the American Society of Clinical Oncology (ASCO) showed ZYTIGA (abiraterone acetate) may prove to be an important new treatment option for metastatic prostate cancer patients prior to receiving chemotherapy.

2 Jun 2012

ENTA announces availability of first non-invasive oral cancer prevention test

Oral cancer is one of the few cancers still on the rise, claiming the lives of as many Americans as melanoma and has shown a recent increase in young, non-smokers. The important news is that oral cancer can now be prevented.

2 Jun 2012

Mothers who smoke during pregnancy increase risk of asthma in children

African-American and Latino children whose mothers smoked during pregnancy are more likely to suffer from acute asthma symptoms in their teens than asthma sufferers whose mothers did not smoke, according to a new study led by a research team at UCSF.

1 Jun 2012

Foreign-born populations in the U.S. are at increased risk for chronic HBV

The prevalence of chronic hepatitis B virus (HBV) infection in the U.S. may be as high as 2.2 million cases according to a new study now available in Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Jun 2012

LILRB2 receptor plays an important role in keeping stem cells from differentiating

An immune-system receptor plays an unexpected but crucially important role in keeping stem cells from differentiating and in helping blood cancer cells grow, researchers at UT Southwestern Medical Center report today in the journal Nature.

1 Jun 2012

Janssen submits canagliflozin NDA with FDA for treatment of type 2 diabetes

Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.

1 Jun 2012

Einstein receives NIH grant to create new vaccine against TB

The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.

1 Jun 2012

Researchers identify new peptide that can block fibrosis of the skin and lungs

A member of the Scleroderma Foundation's Board of Directors has led a team of researchers who have identified a peptide that can block fibrosis of the skin and lungs, according to a report published today.

31 May 2012

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.

31 May 2012

Study examines how SMIP-016 drug kills CLL cells

A new study has identified a life-and-death signaling role for a molecule on the surface of the immune cells involved in the most common form of chronic leukemia. The finding could lead to more effective therapy for chronic lymphocytic leukemia (CLL), an as yet incurable cancer that occurs in more than 16,000 Americans annually.

31 May 2012

SQI Diagnostics reports net loss of $1,350,000 for second quarter 2012

SQI Diagnostics Inc., a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the three and six months ended March 31, 2012.

31 May 2012

Wellmune minimizes risk of URTI among marathoners

Marathoners taking Wellmune WGP, a natural immune health ingredient, for four weeks experienced an average reduction of 40% in upper respiratory tract infection symptomatic days that commonly afflict long-distance runners, according to new clinical study results presented today at the American College of Sports Medicine 59th annual meeting.

31 May 2012

TAU researcher develops new antibodies to target and destroy cancer cells

Because cancer cells grow very quickly, chemotherapy is designed to target cells whose numbers grow rapidly. But this treatment comes with a heavy price - many healthy cells essential for body functions are also targeted and killed by the toxin. This dangerous side-effect has prompted researchers to seek better and more selective ways to kill cancer cells inside the body.

31 May 2012

Researchers identify mechanism key in drug allergy

Adverse drug reactions are a major issue that cause harm, are costly and restrict treatment options for patients and the development of new drugs. A groundbreaking finding by researchers from the La Jolla Institute for Allergy & Immunology could lead to a new way to dramatically improve drug safety by identifying drugs at risk to cause potentially fatal genetic-linked hypersensitivity reactions before their use in man.

30 May 2012

CRI relaunches Cancer Immunity journal

The Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the discovery and development of safe and effective immunotherapies for cancer, today announced the relaunch of the open access, online journal Cancer Immunity, the official journal of the Cancer Research Institute.

30 May 2012

USPTO issues patent to Corgenix’s AspirinWorks technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks technology.

30 May 2012